Targeted treatments for multiple myeloma: specific role of carfilzomib
Dhivya Sugumar,1 Jesse Keller,2 Ravi Vij2 1Department of Internal Medicine, St Mary’s Health Center, 2Department of Medicine, Division of Oncology, Washington University in St Louis, St Louis, USA Abstract: Carfilzomib is a selective, irreversible proteasome inhibitor, initially approved i...
Saved in:
Main Authors: | Sugumar D (Author), Keller J (Author), Vij R (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2015-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma
by: Samia Shabnaz, et al.
Published: (2024) -
Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib
by: Zhao F, et al.
Published: (2018) -
Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
by: Yi L, et al.
Published: (2024) -
Resveratrol Sensitizes Carfilzomib-Induced Apoptosis via Promoting Oxidative Stress in Multiple Myeloma Cells
by: Qian Li, et al.
Published: (2018) -
Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib
by: Harvey RD
Published: (2014)